Exelixis (EXEL) is drawing attention after a year of strong share performance. The stock is up about 51% over the past 12 months and roughly 171% over three years. Recent trading in Exelixis has been ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Exelixis offers strong growth potential, trading at 14x 2026E EPS, below sector median, with robust oncology franchises and disciplined R&D spending. Cabozantinib remains the near-term growth driver, ...

Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, multicenter, ...

Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the August 2025 expiration. One of the key data points that goes into the price an option buyer is willing to ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model ...

Exelixis Inc. (NASDAQ:EXEL) on Tuesday reported its first quarter of 2025 adjusted earnings of 62 cents per share, compared to 17 cents a year ago, beating the consensus of 36 cents. The ...

・The FDA will now decide on Exelixis’s new application by March 3, 2027. ・A March decision would push a possible U.S. launch out of this year and into 2027. ・William Blair said it was “surprised” by ...